- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07723430
Comparison of High-Flow Nasal Cannula and Tight Face Mask for Maintaining Oxygenation During Rapid Sequence Induction
Comparison of the Effectiveness of High-Flow Oxygen Cannula Versus Tight Face Mask in Maintaining Oxygenation During Rapid Sequence Induction
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Rapid sequence induction (RSI) is the preferred technique for securing the airway in patients at risk of aspiration. Despite standardized airway management protocols, hypoxemia during the apneic period remains one of the most frequent and clinically important complications of RSI. Oxygen desaturation may lead to serious adverse events including cardiac arrhythmias, hemodynamic instability, cardiac arrest, neurological injury, and increased mortality. Effective preoxygenation before induction is therefore essential to maximize oxygen reserves and prolong safe apnea time.
Conventional preoxygenation is commonly performed using a tight face mask delivering 100% oxygen. Although this method is widely accepted, oxygen delivery is interrupted when the face mask is removed for laryngoscopy, potentially reducing oxygen reserves during prolonged intubation attempts. High-Flow Nasal Cannula (HFNC) delivers heated and humidified oxygen at high flow rates with a high inspired oxygen fraction while allowing continuous oxygen administration throughout laryngoscopy and apnea. HFNC also generates low-level positive airway pressure and facilitates clearance of upper airway dead space, which may improve oxygenation during rapid sequence induction.
Previous randomized trials and systematic reviews have produced inconsistent findings regarding the comparative effectiveness of HFNC and conventional face mask preoxygenation. Some studies have demonstrated prolonged safe apnea time and improved oxygenation with HFNC, whereas others have shown similar oxygen saturation between both techniques. Additional randomized controlled trials are required to determine whether HFNC provides clinically meaningful advantages in adult patients undergoing rapid sequence induction.
This single-center, prospective, parallel-group, randomized controlled trial will be conducted at the Department of Anesthesiology, Khyber Teaching Hospital, Peshawar. Eligible adult patients requiring rapid sequence induction for endotracheal intubation in the operating room, emergency department, or intensive care unit will be enrolled after providing informed consent. Participants will be randomly assigned in a 1:1 ratio to receive either High-Flow Nasal Cannula or Tight Face Mask preoxygenation using a computer-generated randomization sequence with allocation concealment through sequentially numbered, opaque, sealed envelopes.
Patients allocated to the intervention group will receive heated, humidified oxygen via High-Flow Nasal Cannula at the protocol-defined flow rate and fraction of inspired oxygen before induction and throughout laryngoscopy until successful endotracheal intubation. Participants allocated to the control group will receive conventional preoxygenation using a tightly fitting face mask delivering 100% oxygen according to standard institutional practice until induction of anesthesia.
The primary outcome will be the lowest peripheral oxygen saturation (SpO₂) recorded from induction until successful tracheal intubation. Secondary outcome measures will include the incidence of oxygen desaturation below 90%, duration of apnea, duration of laryngoscopy, time required for successful intubation, first-pass intubation success, number of intubation attempts, and peri-intubation adverse events including hypotension, arrhythmias, aspiration, and cardiac arrest.
Data will be collected prospectively using standardized case report forms by trained investigators. Statistical analyses will follow the intention-to-treat principle. Continuous variables will be compared using the independent-samples t-test or Mann-Whitney U test as appropriate, whereas categorical variables will be compared using the Chi-square test or Fisher's exact test. A two-sided p-value of less than 0.05 will be considered statistically significant.
The results of this trial are expected to provide high-quality evidence regarding the optimal preoxygenation strategy during rapid sequence induction and may contribute to improved airway management protocols and reduction of peri-intubation hypoxemia in adult patients.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged 18 years or older.
- Patients requiring rapid sequence induction (RSI) for endotracheal intubation in the operating room, emergency department, or intensive care unit.
- Patients in whom both high-flow nasal cannula (HFNC) and tight face mask preoxygenation are technically feasible.
- Patients (or their legally authorized representatives, when applicable) able to provide written informed consent.
Exclusion Criteria:
- Patients requiring immediate crash intubation without sufficient time for preoxygenation.
- Patients with facial deformities, upper airway obstruction, or other conditions preventing the use of either HFNC or a tight face mask.
- Known contraindications or hypersensitivity to medications used for rapid sequence induction.
- Pregnant women.
- Patients younger than 18 years of age.
- Patients with do-not-intubate (DNI) orders.
- Patients already intubated or mechanically ventilated before enrollment.
- Patients who underwent endotracheal intubation within the previous 24 hours.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: High-Flow Nasal Cannula (HFNC)
Participants randomized to this arm will receive preoxygenation using a heated, humidified high-flow nasal cannula delivering oxygen at 60 L/min with an FiO₂ of 100% for 3 minutes before rapid sequence induction.
The HFNC will remain in place during induction and laryngoscopy until successful endotracheal intubation to provide continuous oxygenation throughout the apneic period.
|
Participants assigned to this intervention will receive preoxygenation using a heated, humidified high-flow nasal cannula delivering oxygen at a flow rate of 60 L/min with an inspired oxygen fraction (FiO₂) of 1.0 (100%) for 3 minutes before rapid sequence induction.
Oxygen delivery will be continued throughout the apneic period and laryngoscopy until successful endotracheal intubation.
Autres noms:
|
|
Comparateur actif: Tight Face Mask (TFM)
Participants randomized to this arm will receive standard preoxygenation using a tightly fitting anesthesia face mask delivering 100% oxygen at 15 L/min for 3 minutes before rapid sequence induction. The face mask will be removed immediately before laryngoscopy according to routine clinical practice. These arm titles and descriptions are appropriate for ClinicalTrials.gov registration. The next step will be to link each arm to its corresponding Device Intervention (HFNC and Tight Face Mask). |
Participants assigned to this intervention will receive standard preoxygenation using a tightly fitting anesthesia face mask delivering 100% oxygen at a flow rate of 15 L/min for 3 minutes before rapid sequence induction.
The face mask will be removed immediately before laryngoscopy in accordance with standard clinical practice.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Lowest Peripheral Oxygen Saturation (SpO₂) During Rapid Sequence Induction
Délai: Periprocedural (during rapid sequence induction, from induction of anesthesia until successful endotracheal intubation; approximately 5 minutes).
|
Periprocedural (during rapid sequence induction, from induction of anesthesia until successful endotracheal intubation; approximately 5 minutes).
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Incidence of Oxygen Desaturation
Délai: Periprocedural (during rapid sequence induction, from induction of anesthesia until successful endotracheal intubation; approximately 5 minutes).
|
Periprocedural (during rapid sequence induction, from induction of anesthesia until successful endotracheal intubation; approximately 5 minutes).
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 015/DME/KMC
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .